Inspire Trust Co. N.A. Invests $2.04 Million in DexCom, Inc. (NASDAQ:DXCM)

Inspire Trust Co. N.A. bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 26,200 shares of the medical device company's stock, valued at approximately $2,038,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Novem Group bought a new stake in DexCom during the 4th quarter valued at $845,000. Waverly Advisors LLC acquired a new stake in DexCom in the fourth quarter worth about $258,000. Worldquant Millennium Advisors LLC bought a new position in DexCom in the 4th quarter valued at about $32,262,000. Woodline Partners LP acquired a new position in DexCom during the 4th quarter valued at about $63,338,000. Finally, Waters Parkerson & CO. LLC lifted its stake in shares of DexCom by 1.4% in the 4th quarter. Waters Parkerson & CO. LLC now owns 313,197 shares of the medical device company's stock worth $24,357,000 after acquiring an additional 4,364 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the sale, the executive vice president now directly owns 135,482 shares in the company, valued at approximately $10,002,636.06. This trade represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 13,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the transaction, the executive vice president now owns 105,602 shares in the company, valued at $7,432,268.76. This trade represents a 10.96% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 66,926 shares of company stock worth $4,734,384. 0.32% of the stock is owned by company insiders.

DexCom Stock Performance

Shares of DexCom stock opened at $84.89 on Thursday. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $131.76. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The stock has a market cap of $33.29 billion, a PE ratio of 59.36, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The business has a fifty day simple moving average of $72.99 and a 200-day simple moving average of $77.92.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the previous year, the business posted $0.32 earnings per share. The company's revenue was up 12.5% compared to the same quarter last year. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

DXCM has been the topic of several recent analyst reports. Canaccord Genuity Group upped their target price on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Morgan Stanley lifted their target price on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and raised their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Barclays boosted their target price on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Finally, Piper Sandler reduced their target price on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $98.11.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.